# Hydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC)

> **NCT01026844** · PHASE1 · TERMINATED · sponsor: **Massachusetts General Hospital** · enrollment: 27 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** erlotinib
- **DRUG:** hydroxychloroquine

## Key facts

- **NCT ID:** NCT01026844
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-07
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** slow enrollment
- **Last updated:** 2017-01-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01026844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01026844, "Hydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01026844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*